Exceptional Release of Commercial Cellular Therapy ProductsWednesday, January 30, 2019 January 30 at 11:00 AM ET Webinar |
The registration period for this meeting has ended.
Join FACT on January 30, 2019, at 11:00 am ET, 1600 GMT, for a webinar titled, Exceptional Release of Commercial Cellular Therapy Products. Autologous cellular therapy products can be irreplaceable, and exceptional release of nonconforming products may be necessary to the well-being of patients. FACT-accredited programs are increasingly using autologous products that are licensed by regulatory authorities, and sometimes these products do not meet specifications. In this webinar, presenters will discuss FACT requirements for exceptional release, and then share their centers’ processes for release of nonconforming commercial cellular therapy products in the United States.
Webinar presenters include:
Dr. Phyllis I. Warkentin, Chief Medical Officer of FACT
Dr. Premal Lulla, Baylor College of Medicine, Stem Cell Transplant Program, Texas Children's Hospital and Houston Methodist Hospital
Dr. Elizabeth Shpall, MD Anderson Cord Blood Bank Medical Director, MD Anderson Cellular Therapy Transplant Program Director, and co-director of the MD Anderson CARTOX program.
Dr. Phillip McCarthy, of Roswell Park Comprehensive Cancer Center – Transplant and Cellular Therapy Program for Adult Inpatient, Outpatient, and Pediatric Outpatient Programs - John R. Oishei Children’s Hospital
Registration Fees:These fees are available through 01/30/2019 |
||
| Name | Price | Available To |
| Regular | $100.00 | Webinar Registrants |
| Inspector Fee | $0.00 | Inspector, Inspector Trainee |
| Industry | $500.00 | Industry Representatives |
